DeepMed Research

Beijing Friendship Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1952-01-01

Employees: 1K

Market Cap: -

Website: https://www.bfh.com.cn

Clinical Trials

Multitarget Therapy for Idiopathic Membranous Nephropathy

Phase 4

Completed

Conditions: Efficacy

Interventions: Drug: Prednisone, ciclosporin and mycophenolate mofetil
Drug: Ponticelli Regimen

First Posted Date: 2020-06-11

Last Posted Date: 2022-02-17

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 82

Registration Number: NCT04424862

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Beijing Frienship Hospital, Capital Medical University, Beijing, Beijing, China

Status of Management of Surgery in Beijing During COVID-19

Conditions: Gastrointestinal Disease
Gastric Cancer
Colorectal Cancer

Interventions: Other: no intervention

First Posted Date: 2020-05-26

Last Posted Date: 2020-05-27

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 500

Registration Number: NCT04401124

Effectiveness of Bariatric Surgery for NAFLD/NASH

Recruiting

Conditions: NAFLD
NASH With Fibrosis
Bariatric Surgery Candidate

Interventions: Procedure: OAGB
Procedure: RYGB
Procedure: SG

First Posted Date: 2020-04-29

Last Posted Date: 2024-05-14

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 320

Registration Number: NCT04366999

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China

Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer

Phase 2

Conditions: Gastric Cancer

Interventions: Drug: Camrelizumab for injection, apatinib mesylate and tegio

First Posted Date: 2020-04-14

Last Posted Date: 2020-04-14

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 30

Registration Number: NCT04345783

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China

Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: Apatinib Mesylate tablets combined with S-1 capsules

First Posted Date: 2020-04-08

Last Posted Date: 2020-11-10

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 37

Registration Number: NCT04338438

Effect of CI on Prognosis in the Elderly Patients With ACS

Conditions: Cognitive Impairment
Elderly
Acute Coronary Syndrome

Interventions: Diagnostic Test: MMSE and MoCA

First Posted Date: 2020-02-20

Last Posted Date: 2020-02-20

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 500

Registration Number: NCT04278911

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Phase 2

Conditions: Gastric Cancer

Interventions: Drug: Camrelizumab+Apatinib+Paclitaxel-albumin+S-1

First Posted Date: 2020-02-06

Last Posted Date: 2020-02-06

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 30

Registration Number: NCT04258644

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China

Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer

Phase 2

Conditions: Gastric Cancer

Interventions: Drug: paclitaxel-albumin and S-1

First Posted Date: 2020-02-06

Last Posted Date: 2020-02-06

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 20

Registration Number: NCT04258657

Locations: 🇨🇳
Zhongtao Zhang, Beijing, Beijing, China

Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis

Phase 3

Conditions: Hemophagocytic Lymphohistiocytosis

Interventions: Drug: low dose ruxolitinib
Drug: high dose ruxolitinib

First Posted Date: 2019-10-09

Last Posted Date: 2019-10-29

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 80

Registration Number: NCT04120090

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

Phase 3

Conditions: EBV Infection

Interventions: Drug: PD1 antibody
Drug: lenalidomide

First Posted Date: 2019-09-10

Last Posted Date: 2022-01-05

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 40

Registration Number: NCT04084626

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy